NASDAQ: AUPHAurinia Pharmaceuticals Inc Stock
$15.73-0.48 (-2.96%)
Updated Nov 13, 2026
AUPH Price
$15.73
Fair Value Price
N/A
Market Cap
$2.11B
52 Week Low
$13.52
52 Week High
$19.25
P/E
6.67x
P/B
3.21x
P/S
6.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$321.74M
Earnings
$314.27M
Gross Margin
90.6%
Operating Margin
53.15%
Profit Margin
97.7%
Debt to Equity
0.26
Operating Cash Flow
$177M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AUPH Overview
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AUPH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AUPH
Ranked#43 of 450
Ranked#43 of 450
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.66 | A | |
| $955.47 | A | |
| $11.62 | A |
Be the first to know about important AUPH news, forecast changes, insider trades & much more!
AUPH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AUPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AUPH is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AUPH is good value based on its earnings relative to its share price (6.67x), compared to the US market average (41.11x)
P/E vs Market Valuation
AUPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more AUPH due diligence checks available for Premium users.
Valuation
AUPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
6.67x
Industry
18.56x
Market
41.11x
AUPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
AUPH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
AUPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.21x
Industry
5.14x
AUPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AUPH's financial health
Profit margin
Revenue
$83.7M
Net Income
$31.7M
Profit Margin
37.9%
AUPH's Earnings (EBIT) of $170.99M... subscribe to Premium to read more.
Interest Coverage Financials
AUPH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$825.7M
Liabilities
$168.2M
Debt to equity
0.26
AUPH's short-term assets ($587.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AUPH's short-term assets ($587.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AUPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AUPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$46.4M
Investing
-$175.7M
Financing
-$4.3M
AUPH's operating cash flow ($177.16M)... subscribe to Premium to read more.
Debt Coverage Financials
AUPH vs Biotech Stocks
Aurinia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.